{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:23:14Z","timestamp":1761016994946},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6641,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:p>The use of antihypertensive agents in patients with renal insufficiency necessitates careful consideration of dosages, titration, and monitoring. Renal function must be estimated to appropriately make dosage adjustments for antihypertensives that exhibit extensive renal elimination. Thiazide diuretics are useful in mild degrees of renal insufficiency but loop diuretics become necessary as renal function deteriorates further. With either class, low dosages should be used to prevent hypovolemia, hyponatremia, and hypokalemia which may worsen renal blood flow. Angiotensin\u2010converting enzyme (ACE) inhibitors have become popular because they may have unique renal protective properties. All ACE inhibitors except fosinopril require reduced dosages and\/or less frequent administration in patients with renal insufficiency. It is often necessary to use a diuretic with an ACE inhibitor and special dosing considerations are important. Due to demographic and physiologic characteristics of patients with renal insufficiency, beta blockers are often reserved for patients with other indications for beta blockers such as ischemic heart disease. Several beta blockers are eliminated primarily by the kidney and dosage reductions are necessary for these agents. Calcium antagonists may also have renal protective effects. Because calcium antagonists are metabolized extensively, significant dosage adjustments are not necessary. Data suggest that antihypertensives may slow the decline in renal insufficiency. The pharmacokinetics of several antihypertensives change with renal impairment because of reduced elimination. Therefore, dosage adjustments, slower titration, and less frequent administration are often necessary.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1995.tb04749.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:04:26Z","timestamp":1362769466000},"page":"81-86","source":"Crossref","is-referenced-by-count":11,"title":["Dosing of Antihypertensive Medications in Patients with Renal Insufficiency"],"prefix":"10.1002","volume":"35","author":[{"given":"Barry L.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400070058006"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800312"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92462-5"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000418761","article-title":"Comparison of calcium channel blocker and ACE inhibitor therapy on the progression of renal insufficiency","volume":"81","author":"Zucchelli P","year":"1990","journal-title":"Contr Nephrol"},{"issue":"1","key":"e_1_2_1_6_2","first-page":"94","article-title":"Calcium channel blockers: Effects on progressive renal disease","volume":"17","author":"Zucchelli P","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_1_7_2","first-page":"36","article-title":"The renally compromized older hypertensive: Therapeutic considerations","volume":"46","author":"Weder AB","year":"1991","journal-title":"Geriatrics"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archinte.1993.00410080037006","article-title":"Comparative effects of different antihypertensive treatments on progression of diabetic renal disease","volume":"153","author":"Slataper R","year":"1993","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_9_2","first-page":"25","article-title":"Use of angiotensin\u2010converting\u2010enzyme inhibitors in the management of renal disease","volume":"10","author":"Asher JP","year":"1991","journal-title":"Clin Pharm"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0095-4543(21)00344-4","article-title":"Hypertension and the kidney","volume":"18","author":"Weir MR","year":"1991","journal-title":"Primary Care"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.1987.00370050016004","article-title":"Detection, evaluation, and treatment of renovascular hypertension","volume":"147","author":"Working Group on Renovascular Hypertension","year":"1987","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_12_2","first-page":"1248","article-title":"Hypertension and renal insufficiency: Recognition and management","volume":"45","author":"Moore MA","year":"1992","journal-title":"Am Fam Phys"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410020010002"},{"key":"e_1_2_1_15_2","first-page":"239","article-title":"Antihypertensive effect of hydrochlorothiazide administered once or twice daily","volume":"1","author":"Allen JH","year":"1982","journal-title":"Clin Pharm"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281303"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510060059034"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641968309048828"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archinte.1978.03630350054016","article-title":"Use of diuretics in treatment of hypertension secondary to renal disease","volume":"138","author":"Bank N","year":"1978","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(76)80583-2"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5834.196"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127007701700409"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972133336"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1973.225.4.954"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-99-3-405"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-197804000-00011"},{"key":"e_1_2_1_27_2","first-page":"135d","volume-title":"Drug Facts and Comparisons.","author":"Olin B","year":"1993"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.54"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360230061010"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1986.tb04299.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinte.1990.00040031707020","article-title":"Comparison of the efficacy and safety of a b\u2010blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks","volume":"150","author":"Saunders E","year":"1990","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_32_2","first-page":"379","article-title":"Once\u2010daily treatment of essential hypertension with captopril","volume":"4","author":"Schoenberger JA","year":"1986","journal-title":"J Clin Hypertens"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199019030-00003"},{"issue":"20","key":"e_1_2_1_35_2","first-page":"S173","article-title":"Effects of angiotensin\u2010converting enzyme inhibition on renal hemodynamics in renal artery stenosis","volume":"31","author":"Levenson DJ","year":"1987","journal-title":"Kidney Int"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.8.8.650"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1001\/jama.1980.03310220049028","article-title":"Hyperkalemia resulting from captopril administration","volume":"244","author":"Warren SE","year":"1980","journal-title":"JAMA"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90415-6"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.3.6.528"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002400511"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.35.11.1206"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198912000-00009"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542213"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544358"},{"key":"e_1_2_1_45_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00280129","article-title":"Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function","volume":"42","author":"Soons PA","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/cs0670243","article-title":"Comparison between short\u2010term haemodynamic effects of propranolol and nadolol in essential hypertension: A crossover study","volume":"67","author":"Danesh BJZ","year":"1984","journal-title":"Clin Sci"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(84)80083-9"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02187.x"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209023071007"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01900.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808301701001"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1995.tb04749.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1995.tb04749.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T23:07:39Z","timestamp":1698361659000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1995.tb04749.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1002\/j.1552-4604.1995.tb04749.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04749.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}